Glaxo’s Weight-Loss Petition Relied On “Deeply Flawed” Survey – AHPA
This article was originally published in The Tan Sheet
Executive Summary
The American Herbal Products Association says GlaxoSmithKline used data from a flawed consumer survey when the firm asked FDA to reclassify weight loss claims as disease claims
You may also be interested in...
FDA Warns Of Possible Criminal Charges Against Weight-Loss Product Firms
FDA's enforcement action against 28 weight-loss products found to contain undeclared pharmaceutical ingredients drew applause from GlaxoSmithKline, marketer of alli, the only OTC drug approved for weight loss in the U.S
FDA Warns Of Possible Criminal Charges Against Weight-Loss Product Firms
FDA's enforcement action against 28 weight-loss products found to contain undeclared pharmaceutical ingredients drew applause from GlaxoSmithKline, marketer of alli, the only OTC drug approved for weight loss in the U.S
FDA Warns Of Possible Criminal Charges Against Weight-Loss Product Firms
FDA's enforcement action against 28 weight-loss products found to contain undeclared pharmaceutical ingredients drew applause from GlaxoSmithKline, marketer of alli, the only OTC drug approved for weight loss in the U.S